180 related articles for article (PubMed ID: 29077044)
21. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
Furio L; Pampalakis G; Michael IP; Nagy A; Sotiropoulou G; Hovnanian A
PLoS Genet; 2015 Sep; 11(9):e1005389. PubMed ID: 26390218
[TBL] [Abstract][Full Text] [Related]
22. Attenuated kallikrein-related peptidase activity disrupts desquamation and leads to stratum corneum thickening in human skin equivalent models.
McGovern JA; Meinert C; de Veer SJ; Hollier BG; Parker TJ; Upton Z
Br J Dermatol; 2017 Jan; 176(1):145-158. PubMed ID: 27442805
[TBL] [Abstract][Full Text] [Related]
23. Kallikrein-related peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum.
Stefansson K; Brattsand M; Ny A; Glas B; Egelrud T
Biol Chem; 2006 Jun; 387(6):761-8. PubMed ID: 16800737
[TBL] [Abstract][Full Text] [Related]
24. Multifunctional Serine Protease Inhibitor-Coated Water-Soluble Gold Nanoparticles as a Novel Targeted Approach for the Treatment of Inflammatory Skin Diseases.
Limón D; Fábrega MJ; Calpena AC; Badia J; Baldomà L; Pérez-García L
Bioconjug Chem; 2018 Apr; 29(4):1060-1072. PubMed ID: 29406699
[TBL] [Abstract][Full Text] [Related]
25. Kallikrein-related peptidase 5 contributes to the remodeling and repair of bronchial epithelium.
Lenga Ma Bonda W; Lavergne M; Vasseur V; Brisson L; Roger S; Legras A; Guillon A; Guyétant S; Hiemstra PS; Si-Tahar M; Iochmann S; Reverdiau P
FASEB J; 2021 Oct; 35(10):e21838. PubMed ID: 34582061
[TBL] [Abstract][Full Text] [Related]
26. Characterization of Spink6 in mouse skin: the conserved inhibitor of kallikrein-related peptidases is reduced by barrier injury.
Fischer J; Wu Z; Kantyka T; Sperrhacke M; Dimitrieva O; Koblyakova Y; Ahrens K; Graumann N; Baurecht H; Reiss K; Schröder JM; Proksch E; Meyer-Hoffert U
J Invest Dermatol; 2014 May; 134(5):1305-1312. PubMed ID: 24352040
[TBL] [Abstract][Full Text] [Related]
27. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation.
Borgoño CA; Michael IP; Komatsu N; Jayakumar A; Kapadia R; Clayman GL; Sotiropoulou G; Diamandis EP
J Biol Chem; 2007 Feb; 282(6):3640-52. PubMed ID: 17158887
[TBL] [Abstract][Full Text] [Related]
28. Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases.
Mukai S; Fukushima T; Naka D; Tanaka H; Osada Y; Kataoka H
FEBS J; 2008 Mar; 275(5):1003-17. PubMed ID: 18221492
[TBL] [Abstract][Full Text] [Related]
29. Hyaluronan Oligosaccharides Improve Rosacea-Like Phenotype through Anti-Inflammatory and Epidermal Barrier-Improving Effects.
Lee SG; Yoon MS; Kim DH; Shin JU; Lee HJ
Ann Dermatol; 2020 Jun; 32(3):189-196. PubMed ID: 33911737
[TBL] [Abstract][Full Text] [Related]
30. Dichotomous effect of ultraviolet B on the expression of corneodesmosomal enzymes in human epidermal keratinocytes.
Nin M; Katoh N; Kokura S; Handa O; Yoshikawa T; Kishimoto S
J Dermatol Sci; 2009 Apr; 54(1):17-24. PubMed ID: 19118981
[TBL] [Abstract][Full Text] [Related]
31. Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.
Walker AL; Denis A; Bingham RP; Bouillot A; Edgar EV; Ferrie A; Holmes DS; Laroze A; Liddle J; Fouchet MH; Moquette A; Nassau P; Pearce AC; Polyakova O; Smith KJ; Thomas P; Thorpe JH; Trottet L; Wang Y; Hovnanian A
Bioorg Med Chem Lett; 2019 Oct; 29(20):126675. PubMed ID: 31521475
[TBL] [Abstract][Full Text] [Related]
32. 3-Acyltetramic acids as a novel class of inhibitors for human kallikreins 5 and 7.
de Souza AS; Pacheco BDC; Pinheiro S; Muri EMF; Dias LRS; Lima CHS; Garrett R; de Moraes MBM; de Souza BEG; Puzer L
Bioorg Med Chem Lett; 2019 May; 29(9):1094-1098. PubMed ID: 30833107
[TBL] [Abstract][Full Text] [Related]
33. The Th2 cytokine, interleukin-4, abrogates the cohesion of normal stratum corneum in mice: implications for pathogenesis of atopic dermatitis.
Hatano Y; Adachi Y; Elias PM; Crumrine D; Sakai T; Kurahashi R; Katagiri K; Fujiwara S
Exp Dermatol; 2013 Jan; 22(1):30-5. PubMed ID: 23173934
[TBL] [Abstract][Full Text] [Related]
34. Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia.
Swedberg JE; de Veer SJ; Harris JM
Biol Chem; 2010 Apr; 391(4):357-74. PubMed ID: 20180638
[TBL] [Abstract][Full Text] [Related]
35. Physiological and pathological roles of kallikrein-related peptidases in the epidermis.
Kishibe M
J Dermatol Sci; 2019 Aug; 95(2):50-55. PubMed ID: 31279501
[TBL] [Abstract][Full Text] [Related]
36. Expression of serine protease inhibitors in epidermal keratinocytes is increased by calcium but not 1,25-dihydroxyvitamin D
Kobashi M; Morizane S; Sugimoto S; Sugihara S; Iwatsuki K
Br J Dermatol; 2017 Jun; 176(6):1525-1532. PubMed ID: 27797397
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional gene silencing of kallikrein 5 and kallikrein 7 using siRNA prevents epithelial cell detachment induced by alkaline shock in an in vitro model of eczema.
Britland S; Hoyle M
Biotechnol Prog; 2012; 28(2):485-9. PubMed ID: 22095688
[TBL] [Abstract][Full Text] [Related]
38. Bioavailability and activity of natural food additive triterpenoids as influenced by protein.
Peng W; Ding F; Jiang YT; Peng YK
J Agric Food Chem; 2014 Mar; 62(10):2271-83. PubMed ID: 24548018
[TBL] [Abstract][Full Text] [Related]
39. Phytocomponents of triterpenoids, oleanolic acid and ursolic acid, regulated differently the processing of epidermal keratinocytes via PPAR-alpha pathway.
Lee HK; Nam GW; Kim SH; Lee SH
Exp Dermatol; 2006 Jan; 15(1):66-73. PubMed ID: 16364033
[TBL] [Abstract][Full Text] [Related]
40. Protease-activated Receptor-2 (PAR-2)-mediated Nf-κB Activation Suppresses Inflammation-associated Tumor Suppressor MicroRNAs in Oral Squamous Cell Carcinoma.
Johnson JJ; Miller DL; Jiang R; Liu Y; Shi Z; Tarwater L; Williams R; Balsara R; Sauter ER; Stack MS
J Biol Chem; 2016 Mar; 291(13):6936-45. PubMed ID: 26839311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
